Sanofi Kicks Out CEO Hudson: Another One Bites the Dust

• Sanofi terminates Paul Hudson's CEO tenure after a six-year run marked by slow progress in drug pipeline development.
• Belén Garijo, former head of Merck KGaA, steps in as the new CEO to revitalize Sanofi's growth and strategy.
• Hudson's departure highlights a broader trend of leadership changes in European pharmaceutical giants, including GSK and Novo Nordisk.
• Sanofi's shares declined following the announcement, reflecting market uncertainty regarding Garijo's ability to swiftly address the company's challenges.

Hudson's Hustle Ends

Alright, listen up. This is Tony Montana, and I'm tellin' ya, in this business, you either make the money or you get made. This Paul Hudson guy, he was supposed to be the big shot at Sanofi, right? Six years he had, and what he got? A kick in the ass. Seems like he couldn't get those drugs rollin' fast enough, and the vaccine game? Fuggedaboutit. Even Trump was giving him a hard time. In this world, you gotta deliver, or you're out.

New Boss in Town

So now they bringin' in this Belén Garijo broad from Merck. Never heard of her, but these analysts are already cryin' she ain't got the profile. Profile? What's that gonna do, sell more pills? She better be ready to hustle, because Sanofi's got problems. They need new hits, 'cause their asthma drug, Dupixent, is gonna lose its patents soon. They need money now and she better get it. This whole game reminds me of another story, similar to OpenAI's Potent Elixir Acquisition Unlocks New Health Frontiers, where new players enter the scene promising magic bullets but often facing unforeseen challenges. In this business, like I always say, you gotta make the first move.

The Revolving Door of CEOs

Hudson ain't the only one gettin' the boot. GSK and Novo Nordisk, they got new bosses too. What's goin' on? Seems like these big pharma companies are always shakin' things up, looking for the next miracle worker. But let me tell you something, there are no miracles, you need to make things happen. They need someone with the experience, that will bring in the cash and the guns, not just promises and talks.

Sanofi's Stumble

The numbers don't lie. Sanofi's stock is down, and they had some bad luck with their trials in 2025. All this while Hudson was in charge. He even admitted things weren't movin' fast enough. 'We have to be a little bit patient,' he said. Patient? In this business, you can't be patient. Time is money, and money is power. They need to act or they are screwed.

Chasing the Dragon...I mean, Next Big Drug

Hudson was chasin' acquisitions, tryin' to find the next big thing to replace Dupixent. But he couldn't find it. Now this new lady, Garijo, she's gotta find it, and fast. And she needs to act on her own. She has to make the rules and she can't take orders from these big shot corporate fat cats.

Money Talks, Bullshit Walks

Since Hudson took over, shareholders made some money, but not enough. AstraZeneca and GSK made way more. That's the bottom line. In this world, you're judged by what you bring to the table. And if you ain't bringin' the money, you're just another dead man walkin'.